The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 04, 2022

Filed:

Nov. 17, 2016
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Changyu Wang, Union City, CA (US);

Nils Lonberg, Woodside, CA (US);

Alan J. Korman, Piedmont, CA (US);

Mark J. Selby, San Francisco, CA (US);

Mohan Srinivasan, Cupertino, CA (US);

Karla A. Henning, Milpitas, CA (US);

Michelle Minhua Han, Piedmont, CA (US);

Guodong Chen, East Brunswick, NJ (US);

Richard Y. Huang, Bridgewater, NJ (US);

Indrani Chakraborty, Fremont, CA (US);

Haichun Huang, Fremont, CA (US);

Susan Chien-Szu Wong, Fremont, CA (US);

Huiming Li, Lexington, MA (US);

Bryan C. Barnhart, San Francisco, CA (US);

Aaron P. Yamniuk, Lawrenceville, NJ (US);

Ming Lei, Princeton, NJ (US);

Liang Schweizer, Shanghai, CN;

Sandra V. Hatcher, Hillsborough, NJ (US);

Arvind Rajpal, San Francisco, CA (US);

Assignee:

BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); C07K 16/2818 (2013.01); C07K 16/2878 (2013.01); G01N 33/574 (2013.01); G01N 33/6863 (2013.01); A61K 2039/507 (2013.01); A61K 2039/572 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/732 (2013.01); C07K 2317/75 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.


Find Patent Forward Citations

Loading…